Biomarker Analysis in COVID and Post-COVID Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 48
- Locations
- 1
- Primary Endpoint
- Biomarker analysis in CSF
Study Overview
Brief Summary
Headache is one of the most common neurological manifestations of COVID-19. However, it is unclear whether chronic headache after the initial diagnosis, is associated with ongoing damage of the central nervous system. We investigate cpost-COVID-19 patients with persistent headache lasting longer than 3 weeks, to hospitalized acute COVID-19 patients with neurological symptoms and to other non-COVID-19 disease-controls. Readout are neurologial and glial biomarkers in CSF.
Detailed Description
Measurements of neuronal and glial markers in CSF were performed on a SIMOA analyzer (Quanterix) using the Neurology 4-Plex A (Nf-L, Tau, GFAP, UCH-L1) kit.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Diagnosis of COVID, Parkinson's disease, primary headache, Multiples Sclerosis, facial paralysis
- •Persistent post-COVID-19 headache after 3 months of infection
- •Post COVID-patients without persistent headache
- •must be able to perform lumbar puncture
- •Exclusion criteria
- •unknown history of COVID infection
- •lumbar puncture not possible
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Biomarker analysis in CSF
Time Frame: after 3 months of initial infection
Levels of Nf-L, Tau, GFAP, UCH-L1 in CSF
Secondary Outcomes
No secondary outcomes reported
Investigators
Laura de Boni
Principal investigator
University Hospital, Bonn